X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs ASTRAZENECA PHARMA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA ASTRAZENECA PHARMA SUN PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 16.7 95.2 17.6% View Chart
P/BV x 3.4 13.6 24.9% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 SUN PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
ASTRAZENECA PHARMA
Mar-14
SUN PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs8421,285 65.5%   
Low Rs572634 90.3%   
Sales per share (Unadj.) Rs131.6189.6 69.4%  
Earnings per share (Unadj.) Rs32.7-0.2 -16,062.2%  
Cash flow per share (Unadj.) Rs38.03.8 987.8%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs152.768.6 222.5%  
Shares outstanding (eoy) m2,399.2625.00 9,597.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.45.1 106.2%   
Avg P/E ratio x21.6-4,712.7 -0.5%  
P/CF ratio (eoy) x18.6249.6 7.5%  
Price / Book Value ratio x4.614.0 33.1%  
Dividend payout %10.70-   
Avg Mkt Cap Rs m1,696,87723,988 7,074.0%   
No. of employees `00017.51.6 1,123.5%   
Total wages/salary Rs m49,0231,605 3,055.2%   
Avg. sales/employee Rs Th18,028.33,040.2 593.0%   
Avg. wages/employee Rs Th2,798.81,029.2 271.9%   
Avg. net profit/employee Rs Th4,479.5-3.3 -137,200.1%   
INCOME DATA
Net Sales Rs m315,7844,740 6,662.5%  
Other income Rs m6,23292 6,766.0%   
Total revenues Rs m322,0164,832 6,664.5%   
Gross profit Rs m100,893-130 -77,729.4%  
Depreciation Rs m12,648101 12,497.5%   
Interest Rs m3,9980-   
Profit before tax Rs m90,479-139 -65,139.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m12,1165 238,029.5%   
Profit after tax Rs m78,462-5 -1,541,499.0%  
Gross profit margin %31.9-2.7 -1,166.7%  
Effective tax rate %13.4-3.7 -365.4%   
Net profit margin %24.8-0.1 -23,136.9%  
BALANCE SHEET DATA
Current assets Rs m329,5372,726 12,086.9%   
Current liabilities Rs m178,8702,435 7,345.8%   
Net working cap to sales %47.76.1 776.0%  
Current ratio x1.81.1 164.5%  
Inventory Days Days7974 107.1%  
Debtors Days Days8341 204.2%  
Net fixed assets Rs m204,7661,035 19,778.4%   
Share capital Rs m2,39950 4,798.6%   
"Free" reserves Rs m363,997942 38,624.5%   
Net worth Rs m366,3971,716 21,351.8%   
Long term debt Rs m14,3610-   
Total assets Rs m614,1024,156 14,776.3%  
Interest coverage x23.6NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.51.1 45.1%   
Return on assets %13.4-0.1 -10,963.8%  
Return on equity %21.4-0.3 -7,219.5%  
Return on capital %24.80-  
Exports to sales %05.7 0.0%   
Imports to sales %06.5 0.0%   
Exports (fob) Rs mNA270 0.0%   
Imports (cif) Rs mNA306 0.0%   
Fx inflow Rs m44,118375 11,777.4%   
Fx outflow Rs m24,484470 5,207.7%   
Net fx Rs m19,634-96 -20,548.4%   
CASH FLOW
From Operations Rs m70,822-8 -874,346.9%  
From Investments Rs m-42,216-146 28,974.6%  
From Financial Activity Rs m-22,854862 -2,650.6%  
Net Cashflow Rs m6,107709 861.9%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.1 0.3 1,710.0%  
FIIs % 23.0 15.7 146.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 9.1 91.2%  
Shareholders   133,026 12,856 1,034.7%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  CADILA HEALTHCARE  GSK PHARMA  PLETHICO PHARMA  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Steady Despite North Korea Threat(RoundUp)

Global financial markets ended the week on a flat note despite North Korea once again threatening to test a hydrogen bomb in the Pacific Ocean.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Rule-Based Investing Can Make A Lot of Money(The 5 Minute Wrapup)

Sep 16, 2017

We take a glimpse of Equitymaster's results from rule based investing.

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Sep 22, 2017 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - VENUS REMEDIES COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS